Fingolimod: a review of its use in relapsing-remitting multiple sclerosis. - Wikidata - wikimedia - TriplyDB

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

http://www.wikidata.org/entity/Q30838717

about

Routes of administration and dose optimization of soluble antigen arrays in mice with experimental autoimmune encephalomyelitis.Toward a Cancer Drug of Fungal Origin Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo.Concise Review: Pancreatic Cancer and Bone Marrow-Derived Stem Cells.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Severe murine limb-girdle muscular dystrophy type 2C pathology is diminished by FTY720 treatment.Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.Cellular and molecular mechanisms of neurodevelopmental disorders.CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema.Pien Tze Huang Alleviates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mice by Regulating Th1 and Th17 Cells

P2860

Q35032669-2C4F5746-A911-4F87-9D87-A26875DA35E1 Q35596957-059891E7-551B-4DDD-9E4B-38276340090C Q38812925-75A97535-3D34-4F7F-9809-6664D9228A89 Q38842731-67F6B304-3FF4-4902-A6D8-7BF4620F18DC Q38960854-BB9E7CC3-05A1-469F-8496-0D15AC28E2AF Q41019141-803764B6-6AB3-4A80-B53F-DB2A2AD2A58B Q42011721-9988BE94-8E23-4135-891D-73F3A5CFEBD2 Q43172226-2339A249-0F83-43F9-B8E2-C4FB07AB0302 Q55310033-7D4D3A06-0F7B-43B3-99BE-6FF15AE9A5E4 Q59133634-6A74BB82-1FD3-489A-AA33-7022F29BE3BC

P2860

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

http://www.wikidata.org/entity/Q30838717

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

@ast

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

@en

type

label

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

@ast

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

@en

prefLabel

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

@ast

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

@en

P1433

Q30838717-7966CB82-27D1-4ACA-8123-9DF9475C52A3

P1476

Q30838717-4809BD7F-F1A2-419B-92C1-1199F0C02DE2

P2093

Q30838717-C2EEE66C-F4AF-4EB8-B5B0-62D072246635

P2860

Q30838717-06A6E69C-872D-4957-BF84-DA72E2BC8641

Q30838717-16DF2BB6-1568-423C-94FC-38DB157A7DE3

Q30838717-1B55C780-B9ED-41C3-B296-1B1C3F9A61E5

Q30838717-1FA3757D-85F2-464D-BBEB-47EB706703C9

Q30838717-219FCD30-CF00-4A2D-B008-F21ECCB8F863

Q30838717-23BD242A-85D9-4D65-BF4C-846BA5717CEB

Q30838717-28F53C02-D93F-4EFF-AAC4-E0C0A70349DC

Q30838717-2EBD08CE-2E2A-4913-A6CD-29011D982353

Q30838717-357847E4-1D62-4076-A345-7DA46BA49966

Q30838717-35B4882B-BF9F-42F1-BCFA-87D49FDEC933

P2888

Q30838717-6493E156-8B9B-41F3-965E-6F0C32F52EB8

P304

Q30838717-9D5640E1-614C-4281-9657-34498D0744FD

P31

Q30838717-71FA50A2-A196-4E6C-9FBD-B49E0A7EC2F8

P356

Q30838717-59B248CA-F6B0-4416-AAC2-8BA801433F35

P433

Q30838717-C2899AEC-358B-4DF2-8A94-AF57E3E80C95

P478

Q30838717-14905ABD-4C94-44D5-B1C6-9BC6DD7C3328

P577

Q30838717-2D82A096-6D3E-4C5F-AEEC-583936314613

P5875

Q30838717-94CB8B4A-C2A2-4E11-BE04-510BD61BDA0F

P6179

Q30838717-874AC4AC-C6BD-4CF4-B411-9C9F87807FBB

P698

Q30838717-BBF773A0-A61F-410D-8CCB-A2E3F771D174

P921

Q30838717-3F9D5923-ACA6-4586-908D-97CF79F5441F

Q30838717-81FA38F4-0A91-411F-A98D-E031B7CAD562

P356

S40265-014-0264-Y

P1433

P1476

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

@en

P2093

Mark Sanford

http://www.w3.org/2001/XMLSchema#string

P2860

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Multiple sclerosis

Fingolimod treatment in multiple sclerosis leads to increased macular volume.

Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.

P2888

s40265-014-0264-y

P304

1411-1433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-014-0264-Y

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264246991

http://www.w3.org/2001/XMLSchema#string

P6179

1034998631

http://www.w3.org/2001/XMLSchema#string

P698

25063048

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

multiple sclerosis